A five-part series, with each session including two expert presentations and a Q&A.
The goal of the inaugural MAP series was to educate health care providers and team members, including industry partners, about the basics of genomics, understanding genomic reports including variants of unknown significance, and therapeutic application. Ultimately, we sought to accelerate the clinical development and clinical application of precision diagnostics and therapies for patients with cancer and to improve the outcomes for patients who are battling this difficult-to-treat disease.
- Identify the therapeutic strategies to target actionable oncogenic drivers in non-small cell lung cancer.
- Appraise the various alterations in the PI3K and MAPK pathway and potential therapeutic strategies.
- Review the role of tumor mutation burden and other tissue-agnostic biomarkers in mediating response to immunotherapy.
- Examine the components of antibody drug-conjugates and therapeutic role in solid tumors.